Phenotypic spectrum of polycystic ovary syndrome in a tertiary care rural hospital in Eastern India

Nephy T. S. Darrshini; Joyeeta Mondal; Sanat Bala; Maitri Barua; Amit Kyal; Manas Kumar Saha

doi:10.18203/2320-1770.ijrcog20260175

Authors

Nephy T. S. Darrshini Department of Obstetrics and Gynecology, Diamond Harbor Government Medical College and Hospital, South 24 Parganas, West Bengal, India
Joyeeta Mondal Department of Obstetrics and Gynecology, Diamond Harbor Government Medical College and Hospital, South 24 Parganas, West Bengal, India
Sanat Bala Department of Obstetrics and Gynecology, Diamond Harbor Government Medical College and Hospital, South 24 Parganas, West Bengal, India
Maitri Barua Department of Obstetrics and Gynecology, Diamond Harbor Government Medical College and Hospital, South 24 Parganas, West Bengal, India
Amit Kyal Department of Obstetrics and Gynecology, Diamond Harbor Government Medical College and Hospital, South 24 Parganas, West Bengal, India
Manas Kumar Saha Department of Obstetrics and Gynecology, Diamond Harbor Government Medical College and Hospital, South 24 Parganas, West Bengal, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20260175

Keywords:

PCOS phenotypes, Rotterdam criteria, Cardiovascular risk, Reproductive health, Hormonal profile, Metabolic syndrome

Abstract

Background: PCOS is a common, complicated endocrine disorder affecting women of reproductive age causing wide-spectrum of clinical, metabolic and hormonal abnormalities whose characteristics are poorly understood. This research will investigate the phenotypic prevalence of PCOS as well as clinical, hormonal and metabolic aspects to identify risks and therapeutic requirements.

Methods: The Rotterdam criteria were used to classify 204 women with PCOS into four phenotypes: A (hyperandrogenism + oligo/anovulation + polycystic ovaries), B (hyperandrogenism + oligo/anovulation), C (hyperandrogenism + polycystic ovaries) and D (oligo/anovulation + polycystic ovaries). BMI, waist circumference, hip circumference, waist-to-hip ratio and clinical features (menstrual abnormalities, acanthosis nigricans) were examined. To compare the phenotypes, luteinizing hormone, follicle-stimulating hormone, testosterone and metabolic indicators (lipid profiles, glucose metabolism parameters) were examined. The phenotypes were also examined for the prevalence of metabolic syndrome.

Results: A (58.33%) was the most prevalent phenotype, followed by D (32.84%), C (4.90%) and B (3.43%). Phenotype A had the highest BMI and most menstrual abnormalities and also the highest LH/FSH ratio and the highest testosterone, indicating a severe endocrine disorder. Phenotype A also had the worst lipid profile and the highest metabolic syndrome (24.37%).

Conclusion: Phenotype A is the most severe form of PCOS, characterized by clinical, metabolic and hormonal abnormalities and increases the risk of cardiovascular and metabolic problems. These data suggest that PCOS therapy should be phenotype-specific to address the risks and health problems of each phenotype and treatment individualised.

Metrics

Metrics Loading ...

References

Liu J, Wu Q, Hao Y. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Hum Reprod. 2021;36(4):1108-19. DOI: https://doi.org/10.1093/humrep/deaa371

Kahn JA. Polycystic Ovary Syndrome. Adolescent Med. 2008:165-74. DOI: https://doi.org/10.1016/B978-032304073-0.10023-8

Ruze R, Liu T, Zou X. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:116-21. DOI: https://doi.org/10.3389/fendo.2023.1161521

Bharali MD, Rajendran R, Goswami J, Singal K, Rajendran V. Prevalence of Polycystic Ovarian Syndrome in India: A Systematic Review and Meta-Analysis. Cureus. 2022;14(12):32351. DOI: https://doi.org/10.7759/cureus.32351

Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Asian Pac J Cancer Prev. 2017;18(1):17-21.

Lujan ME, Chizen DR, Pierson RA. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can. 2008;30(8):671-9. DOI: https://doi.org/10.1016/S1701-2163(16)32915-2

Louwers YV, Laven JSE. Characteristics of polycystic ovary syndrome throughout life. Ther Adv Reprod Health. 2020;14:2638. DOI: https://doi.org/10.1177/2633494120911038

Dennett CC, Simon J. The Role of Polycystic Ovary Syndrome in Reproductive and Metabolic Health: Overview and Approaches for Treatment. Diabetes Spectr. 2015;28(2):116-20. DOI: https://doi.org/10.2337/diaspect.28.2.116

Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673-683. DOI: https://doi.org/10.1093/humupd/dml036

Meyer AA, Kundt G, Lenschow U, Schuff-Werner P, Kienast W. Improvement of Early Vascular Changes and Cardiovascular Risk Factors in Obese Children After a Six-Month Exercise Program. J Am Coll Cardiol. 2006;48(9):1865-70. DOI: https://doi.org/10.1016/j.jacc.2006.07.035

De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C, Foti DP. Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Front Endocrinol. 2018;9:2. DOI: https://doi.org/10.3389/fendo.2018.00002

Himelein MJ, Thatcher SS. Depression and body image among women with polycystic ovary syndrome. J Health Psychol. 2006;11(4):613-625. DOI: https://doi.org/10.1177/1359105306065021

Aroda VR, Ratner RE. Metformin and Type 2 Diabetes Prevention. Diabetes Spectr. 2018;31(4):336-42. DOI: https://doi.org/10.2337/ds18-0020

Lathia T, Joshi A, Behl A, et al. A Practitioner's Toolkit for Polycystic Ovary Syndrome Counselling. Indian J Endocrinol Metab. 2022;26(1):17-25. DOI: https://doi.org/10.4103/ijem.ijem_411_21

Rojas J, Chávez M, Olivar L, et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014;2014:7150. DOI: https://doi.org/10.1155/2014/719050

Purwar A, Nagpure S. Insulin Resistance in Polycystic Ovarian Syndrome. Cureus. 2022;14(10):351. DOI: https://doi.org/10.7759/cureus.30351

Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41. DOI: https://doi.org/10.1186/1741-7015-8-41

Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15(4):477-88. DOI: https://doi.org/10.1093/humupd/dmp008

Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene. Indian J Endocrinol Metab. 2019;23(3):587.

Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83(6):1717-23. DOI: https://doi.org/10.1016/j.fertnstert.2005.01.096

Głuszak O, Stopińska-Głuszak U, Glinicki P, et al. Phenotype and Metabolic Disorders in Polycystic Ovary Syndrome. ISRN Endocrinol. 2012;3:5862. DOI: https://doi.org/10.5402/2012/569862

Pikee S, Shivani S, Jayshree B. Endocrine and Metabolic Profile of Different Phenotypes of Polycystic Ovarian Syndrome. J Obstet Gynaecol India. 2016;66(1):560-6. DOI: https://doi.org/10.1007/s13224-016-0898-7

Parveen S, Khan S, Ahsan H, Manger PT, Gupta B, Alam R. Fat mass and Obesity Associated (FTO) gene and polycystic ovary syndrome: Insight into pathogenesis and association with insulin resistance. Hum Nutr Metab. 2022;30:200174. DOI: https://doi.org/10.1016/j.hnm.2022.200174

Welt CK, Carmina E. Clinical review: Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J Clin Endocrinol Metab. 2013;98(12):4629-38. DOI: https://doi.org/10.1210/jc.2013-2375

Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG. 2009;116(12):1633-9. DOI: https://doi.org/10.1111/j.1471-0528.2009.02347.x

Le NSV, Le MT, Nguyen ND, Tran NQT, Nguyen QHV, Cao TN. A Cross-Sectional Study on Potential Ovarian Volume and Related Factors in Women with Polycystic Ovary Syndrome from Infertile Couples. Int J Womens Health. 2021;13:793-801. DOI: https://doi.org/10.2147/IJWH.S329082

Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223-36. DOI: https://doi.org/10.1056/NEJMra041536

Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene. Indian J Endocrinol Metab. 2019;23(3):326-31. DOI: https://doi.org/10.4103/ijem.IJEM_30_19

Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-92. DOI: https://doi.org/10.1210/jc.2013-2350

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9. DOI: https://doi.org/10.1210/jc.2003-032046

Das D, Das I, Das J, Koyal SK, Khuda-Bukhsh AR. Efficacy of two commonly used potentized homeopathic drugs, Calcarea carbonica and Lycopodium clavatum, used for treating polycystic ovarian syndrome (PCOS) patients: II. Modulating effects on certain associated hormonal levels. TANG. 2016;6(1):7. DOI: https://doi.org/10.5667/tang.2015.0032

Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol. 2007;67(5):735-42. DOI: https://doi.org/10.1111/j.1365-2265.2007.02954.x